A First-in-human Study to Evaluate the Safety and Tolerability of AZD8853 in Participants with Selected Advanced/Metastatic Solid Tumours

Trial Identifier: D9450C00001
Sponsor: AstraZeneca
Collaborator:
ImaginAb, Inc.
NCTID:: NCT05397171
Start Date: June 2022
Primary Completion Date: June 2023
Study Completion Date: June 2023
Condition: Lung Cancer; Colorectal Cancer; Bladder - Other

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description
English Version
English (Canada) Translation

Trial Locations

Country Location
CA, ON Ottawa, ON, CA, K1H 8L6
CA, Ontario Toronto, Ontario, CA, M5G 1X5
US, GA Atlanta, GA, US, 30322
US, MO Saint Louis, MO, US, 63110
US, RI Providence, RI, US, 02903
US, WA Seattle, WA, US, 98109